Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 2.

Journal Article

Lin, C. C., Joerger, M., Grell, P., Chiappori, A. A., Leal, T. A., Kasper, S., Jerusalem, G., Goncalves, A., Wolf, J., De Braud, F., de Jonge, M. J. A., Otero, J., Chhagan, S., Cipolletta, D., Morris, E., Chowdhury, N. R., Hurtado, F. K. and Tan, D. S. (2020). Continuous vs intermittent adenosine 2A receptor (A2AR) inhibition in preclinical colon cancer (CC) models and in a Phase (Ph) II study of taminadenant (NIR178) + spartalizumab (PDR001) in patients ( pts) with non-small cell lung cancer (NSCLC). Eur. J. Cancer, 138. S. S12 - 2. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852

Wolf, J., Seto, T., Han, J-Y., Reguart, N., Garon, E. B., Groen, H. J. M., Tan, D. S., Hida, T., de Jonge, M. J. A., Orlov, S. V., Smit, E. F., Souquet, P-J., Vansteenkiste, J. F., Giovannini, M., Le Mouhaer, S., Robeva, A., Waldron-Lynch, M. and Heist, R. S. (2018). Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with MET Delta ex14 mutated advanced non-small cell lung cancer (NSCLC). Ann. Oncol., 29. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

This list was generated on Wed Dec 7 20:57:17 2022 CET.